{
    "clinical_study": {
        "@rank": "40430", 
        "arm_group": {
            "arm_group_label": "CI-994 Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months."
        }, 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of CI-994 in treating patients who have\n      advanced myeloma."
        }, 
        "brief_title": "CI-994 in Treating Patients With Advanced Myeloma", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the antitumor activity of CI-994 in patients with advanced myeloma.\n      II. Determine the response rate, response duration, and overall survival of this patient\n      population with this treatment regimen. III. Determine the safety of this treatment in these\n      patients.\n\n      OUTLINE: This is a multicenter study. Patients receive CI-994 orally daily. Treatment\n      continues in the absence of disease progression or unacceptable toxicity. Patients are\n      followed for 30 days and then every 2 months.\n\n      PROJECTED ACCRUAL: A total of 8-63 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed stage IIA or IIIA myeloma with a\n        measurable M- component in the serum or urine Progressing disease after conventional\n        chemotherapy\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:\n        Greater than 8 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet\n        count at least 75,000/mm3 (transfusion independent) Hepatic: Bilirubin no greater than 2\n        times upper limit of normal (ULN) AST/ALT no greater than 2 times ULN Renal: Creatinine no\n        greater than 1.5 times ULN Calcium no greater than 12 mg/dL Other: Not pregnant or nursing\n        Fertile patients must use effective contraception No life threatening illness unrelated to\n        the tumor No concurrent serious infection No prior malignancy within the past 3 years\n        except nonmelanoma skin cancer or carcinoma in situ of the cervix Must be capable of\n        swallowing intact medication capsules No medical or psychiatric condition that would\n        prevent written informed consent\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 14 days since prior immunologic\n        agents No concurrent immunologic agents Chemotherapy: See Disease Characteristics At least\n        3 weeks since prior chemotherapy No concurrent chemotherapy Endocrine therapy: At least 2\n        weeks since prior high dose corticosteroids No concurrent anticancer hormonal therapy No\n        concurrent corticosteroids Radiotherapy: At least 3 weeks since prior radiotherapy and\n        recovered No concurrent radiotherapy Surgery: Not specified"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005624", 
            "org_study_id": "MCC-11560", 
            "secondary_id": [
                "PD-994-04", 
                "NCI-G00-1758"
            ]
        }, 
        "intervention": {
            "arm_group_label": "CI-994 Treatment", 
            "description": "CI-994 as outlined in treatment arm.", 
            "intervention_name": "CI-994", 
            "intervention_type": "Drug", 
            "other_name": [
                "Oral N-Acetyl Dinaline", 
                "Tacedinaline", 
                "HDAC Inhibitor", 
                "CAS 112522-64-2", 
                "Acetyldinaline", 
                "PD 123654"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Histone Deacetylase Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "refractory multiple myeloma", 
            "stage II multiple myeloma", 
            "stage III multiple myeloma", 
            "plasma cell neoplasm"
        ], 
        "lastchanged_date": "September 21, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MCC-11560"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Phase 2 Study of Oral N-Acetyl Dinaline (CI-994) in the Treatment of Patients With Advanced Myeloma", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Melissa Alsina, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Response Rate according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria.", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005624"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response of duration in months", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Participants surviving at end of study.", 
                "measure": "Number of Participants with Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "description": "Review of adverse events utilizing Common Toxicity Criteria (CTC) V3.", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "5 years"
            }
        ], 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Parke-Davis", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 1997", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }, 
    "geocoordinates": {
        "H. Lee Moffitt Cancer Center and Research Institute": "27.951 -82.457"
    }
}